Maximize your positive impact through the Crystal Ball Event Series by MarketsandMarkets

MarketsandMarkets Advanced Genetic Sequencing CRYSTAL BALL EVENT (Time Zone - EST)

High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event

DNA sequencing is the process of determining the precise order of the nucleotides in DNA. Genome sequencing helps us to understand the genetic biology and has vast potential for medical diagnosis and treatment. DNA sequencing technologies have gone through at least three "generations": Sanger sequencing and Gilbert sequencing were first-generation, pyrosequencing was second-generation, and Illumina sequencing is next-generation.

Advancements in NGS platforms, declining costs of genome sequencing and growing incidence of cancer and increasing applications of NGS in cancer research are the key factors supporting the growth of the market.

Continuous technological innovations in sequencers have enabled the introduction of efficient, portable, and easy-to-use NGS platforms, capable of providing rapid and accurate results and boasting improved turnaround times. The introduction of such products and the technologies behind them provides an immediate competitive edge to players; as a result, prominent companies are increasingly focusing on the research and development of such products to strengthen their market positions and shares.

Many countries are investing in their own national population sequencing programs to understand the link between genetics and diseases. Government organizations are sequencing millions of genomes to advance research and help develop better ways to diagnose and treat cancer, rare diseases, and other conditions. As a result, large sequencing projects can be expected to provide lucrative growth opportunities for market players, given the high-scale adoption of NGS instruments and the use of consumables required in such efforts.

In January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some of the areas of focus of this project are precision health, rare genetic disorders, mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.

In September 2019, a whole-genome sequencing project of USD 224 million was created, forming a partnership of pharmaceutical firms and health experts, which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank, based in Stockport, UK. The project aims to improve health through genetic research and improve the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, diabetes, arthritis, and dementia.

What to Expect

Key
Highlights

  • AI in genomics and precision medicine
  • Advancements in NGS platforms, declining costs of genome sequencing and growing incidence of cancer and increasing applications of NGS in cancer research are the key factors supporting the growth of the market.
  • Genome sequencing helps us to understand the genetic biology and has vast potential for medical diagnosis and treatment.
  • Sequencing as a regular diagnostic test for cancer and rare diseases
  • Human microbiome-based drug development

Crystal Ball:
Through the Speakers Perspective

  • How fast can sequencing be conducted, without compromising on the quality and at a low cost?
  • How can AI and automation help in better genetic sequencing results?
  • What is the level of sensitivity that will be required for advanced genetic sequencing?
  • Can genetic sequencing become affordable for routine testing, or will it continue being used for specific diseases?

Conference Agenda

TOP 10 OPPORTUNITIES IN ADVANCED GENETIC SEQUENCING

90 minutes of brainstorming among 4 great minds which will aim at bringing out a tangible action plan by discussing the question given below:

  • How are genetic sequencing companies managing the security of such a  gigantic volume of data?
  • How can companies optimize the manufacturing processes to be more agile and efficient to achieve a more seamless workflow?
  • What can be done to train more people into performing and analyzing advanced sequencing techniques on crops and microorganisms?
  • Which machine learning approaches can be used to address data limitations so that AI models do not lead to misleading insights or faulty predictions?
  • When can a 100% AI integration into genomics be expected?

Conference Speakers

Confirmed Speakers

Nayanika Chatterjee

Nayanika Chatterjee

Research, MarketsandMarkets

Dr. Anthony Marotta

Dr. Anthony Marotta

Medical Director, Amoy Diagnostics

Jun Yin

Jun Yin

Associate Director, Bioinformatics, Ferring Pharmaceuticals

Amit Shah

Amit Shah

VP -Client Partner, Sales, MarketsandMarkets

Donald L. Davis

Donald L. Davis

President and Principal, 5280 Life Sciences Consulting, LLC

View All Speakers
Connect with us
Top Market Reports | Conferences | Research Insight | Blog | New Reports
© 2021 MarketsandMarkets Research Private Ltd. All rights reserved
Subscribe Newsletter
By subscribing to our mailing list you will always get latest news from us.